Advances in the treatment of newly diagnosed primary central nervous system lymphomas.
- Author:
Liren QIAN
1
;
Ciprian TOMULEASA
;
Ioan Alexandru FLORIAN
;
Jianliang SHEN
;
Ioan Stefan FLORIAN
;
Mihnea ZDRENGHEA
;
Delia DIMA
Author Information
- Publication Type:Review
- Keywords: Primary central nervous system lymphoma; Methotrexate; Whole-brain radiotherapy; Rituximab
- MeSH: Blood-Brain Barrier; Central Nervous System*; Drug Therapy; Incidence; Lymphoma*; Lymphoma, Non-Hodgkin; Methotrexate; Organ Transplantation; Radiotherapy; Risk Factors; Rituximab; Transplants
- From:Blood Research 2017;52(3):159-166
- CountryRepublic of Korea
- Language:English
- Abstract: Primary central nervous system lymphoma (PCNSL) is a type of highly invasive non-Hodgkin lymphoma. With a growing number of organ transplantation and immunosuppressant therapy, the incidence of PCNSL has been growing rapidly in recent years, which is attributed to the increased incidence of HIV/AIDS, a prominent risk factor for developing PCNSL. The rising rate of PCNSL incidence is the highest among the intracranial tumors. In the past 20 years, dozens of clinical trials related to PCNSL have been registered, but adequate therapeutics are still challenging. Currently, the chemotherapy regimens based on high-dose methotrexate and whole-brain radiotherapy are the two main therapeutic options; however, the toxicity associated with those is the main problem that challenges medical researchers. Novel agents and therapeutic strategies have been developed in recent years. In the current review, we describe advances in the treatment of PCNSL and discuss novel therapeutic approaches currently in development, such as the use of rituximab, disruption of the blood-brain barrier, and state-of-the-art radiotherapy.
